Nuvocid (oritavancin) at single or infrequent doses for the treatment of complicated skin and skin structure infections (SIMPLIFI)

Trial Profile

Nuvocid (oritavancin) at single or infrequent doses for the treatment of complicated skin and skin structure infections (SIMPLIFI)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Oritavancin (Primary)
  • Indications Skin and soft tissue infections
  • Focus Therapeutic Use
  • Acronyms SIMPLIFI
  • Sponsors Targanta Therapeutics Corporation
  • Most Recent Events

    • 05 Jun 2017 Characteristics of bacterial isolates data from this study presented at the ASM Microbe 2017
    • 30 Oct 2016 Results presented at the IDWeek 2016
    • 02 May 2011 Results published in Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top